Three Clinical Studies Demonstrating Safety and Efficacy of Treatment for Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D) in Adults

This supplement is sponsored by Salix Pharmaceuticals.
June 19, 2018|Internal Medicine News

Click to read supplement. 

In this supplement to Internal Medicine News, Christine Frissora, MD provides an overview of the burdens that patients with IBS-D experience. Three clinical efficacy and safety studies surrounding an FDA-approved treatment are also examined.

Topics include:

,

  • IBS-D diagnosis and treatment challenges

  • The role of microbial imbalance and altered gut microbiota

  • A treatment option for relief of IBS-D symptoms

Click to read supplement. 

XIFI.0273.USA.18